A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective Anticoagulation Length with low molecular weight heparin In the treatment of Cancer Associated Thrombosis (ALICAT): study protocol for a mixed-methods study
Joanna Smith(Cardiff University), Simon Noble(Marie Curie), Angela Casbard(Medical Research Council), Trevor Baglin(Cambridge University Hospitals NHS Foundation Trust), Jessica Baillie(Cwm Taf University Health Board), Harold Toone(Cardiff University), David Fitzmaurice(University of Warwick), Anthony Maraveyas(University of Hull), David Cohen(University of Missouri), Miriam J. Johnson(University of Hull), Gareth Griffiths(NIHR Evaluation Trials and Studies Coordinating Centre), Peter Rose(Academy of Nutrition and Dietetics), John Bell(University of Leeds), Kerenza Hood(NHS Digital), Alexander T. Cohen(King's College London), Annmarie Nelson(Marie Curie Palliative Care Institute Liverpool)
Cited by 13
Related Papers
Hydrogen Sulfide and Cell Signaling
|The Annual Review of Pharmacology and Toxicology|2011|1.3k
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
|British Journal of Haematology|2012|867
Screening for Atrial Fibrillation
|Circulation|2017|535
Bioactive S-alk(en)yl cysteine sulfoxide metabolites in the genus Allium: the chemistry of potential therapeutic agents
|Natural Product Reports|2005|469
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
|Signal Transduction and Targeted Therapy|2023|457